Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3810944 dose-escalation study in advanced solid tumors
NL-OMON60492Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 3810944 in Nonhematologic neoplasms and melanoma, sponsored by Boehringer Ingelheim. Started Aug 2026; status: recruiting.
02
Drugs
BI 3810944
03
Conditions
Nonhematologic neoplasmsmelanoma
Beyond the preview
Go deeper on NL-OMON60492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60492.